Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Phase 2 study of the Combination of Omacetaxine and Imatinib in the Treatment of Patients with Chronic Myeloid Leukemia (CML) in Advanced Stages or After Failure to Imatinib.

Mohamad Ayoubi, MD, Hagop M. Kantarjian, MD, William Wierda, MD, PhD, Alessandra Ferrajoli, MD, Jody Hiteshew, Zeev Estrov, MD, Jorge Cortes-Franco, MD

Blood (2009) 114 (22): 2193.

https://doi.org/10.1182/blood.V114.22.2193.2193

Published: 2009

Journal Articles

Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study.

Dong-Wook Kim, MD, PhD, Camille Granvil, PhD, Eren Demirhan, John Reynolds, Yu Jin, MSc, Yanfeng Wang, PhD, Michele Baccarani, MD, Jorge Cortes-Franco, MD, Brian J. Druker, MD, Timothy P. Hughes, MD, MBBS, François Guilhot, MD

Blood (2009) 114 (22): 1127.

https://doi.org/10.1182/blood.V114.22.1127.1127

Published: 2009

Journal Articles

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Hagop M. Kantarjian, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Kapil N. Bhalla, MD, Javier Pinilla-Ibarz, MD, PhD, Richard A. Larson, MD, Norbert Gattermann, MD, PhD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD, Jerald P. Radich, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD, MBBS, Giovanni Martinelli, MD, Dong-Wook Kim, MD, PhD, Yaping Shou, MD, PhD, Neil J. Gallagher, MD, PhD, Jim Wang, PhD, Jorge Cortes-Franco, MD, Michele Baccarani, MD, Philipp D. le Coutre, MD

Blood (2009) 114 (22): 1129.

https://doi.org/10.1182/blood.V114.22.1129.1129

Published: 2009

Journal Articles

Outcome of Therapy-Related Acute Promyelocytic Leukemia (t-APL) with or without Arsenic Trioxide (ATO) as a Component of Frontline Therapy.

Farshid Dayyani, MD, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Sherry Pierce, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Jorge Cortes-Franco, MD, Farhad Ravandi, MD

Blood (2009) 114 (22): 1050.

https://doi.org/10.1182/blood.V114.22.1050.1050

Published: 2009

Journal Articles

A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia (APL) Patients (PTS) Who Have Received Prior Therapy with All-Trans Retinoic Acid and Arsenic Trioxide (STAR-1 trial).

Jorge Cortes-Franco, MD, Steven Coutre, MD, Eros Di Bona, MD, Francesco Lo-Coco, Meir Wetzler, MD, Miguel Sanz, MD, PhD, Scott Wieland, MBA, PhD, Jack R. Barber, PhD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 2050.

https://doi.org/10.1182/blood.V114.22.2050.2050

Published: 2009

Journal Articles

A Common but Overlooked Mechanism of BCR-ABL1 Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.

Jean-Marie Bruey, Hagop M. Kantarjian, MD, Wanlong Ma, Chen-Hsiung Yeh, Tai-Sung Lee, Susan O'Brien, Francis Giles, MD, Zeev Estrov, MD, Jorge Cortes-Franco, MD, Maher Albitar, MD

Blood (2009) 114 (22): 2179.

https://doi.org/10.1182/blood.V114.22.2179.2179

Published: 2009

Journal Articles

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

Jorge Cortes-Franco, MD, H. Jean Khoury, MD, FACP, Franck Emmanuel Nicolini, MD, PhD, Selim Corm, Jeffrey H. Lipton, MD,PhD, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, Eric Humphriss, Hagop Kantarjian, MD

Blood (2009) 114 (22): 644.

https://doi.org/10.1182/blood.V114.22.644.644

Published: 2009

Journal Articles

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

Wei-gang Tong, MD, PhD, Tapan Kadia, MD, Gautam Borthakur, MD, Elias Jabbour, MD, Sherry Pierce, RN, Jianqin Shan, PhD, Jorge Cortes-Franco, MD, Farhad Ravandi, MD, William Wierda, MD, PhD, Deborah Thomas, MD, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2009) 114 (22): 3819.

https://doi.org/10.1182/blood.V114.22.3819.3819

Published: 2009

Journal Articles

Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial.

Ruben A. Mesa, MD, Hagop Kantarjian, Ayalew Tefferi, MD, Richard Levy, MD, Kris Vaddi, Susan Erickson-Viitanen, PhD, Deborah A. Thomas, MD, Jorge Cortes-Franco, MD, Gautam Borthakur, MBBS, Animesh D. Pardanani, MBBS, PhD, Zeev Estrov, MD, Srdan Verstovsek, MD, PhD

Blood (2009) 114 (22): 3917.

https://doi.org/10.1182/blood.V114.22.3917.3917

Published: 2009

Journal Articles

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Ricardo Pasquini, MD, Jorge Cortes-Franco, MD, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Zhixiang Shen, MD, PhD, Luis Meillon, MD, Lidia Mongay, MD, PhD, MBA, Dawn F. Eng, Jim Wang, PhD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD

Blood (2009) 114 (22): 4267.

https://doi.org/10.1182/blood.V114.22.4267.4267

Published: 2009

Journal Articles

Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study.

Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Zeev Estrov, MD, Jan A. Burger, MD, PhD, Solly George, Rn, Carol Bivins, Rn, Jorge Cortes-Franco, MD, William M Garrett, MBA, Robert C Newton, PhD, Hagop Kantarjian, MD

Blood (2009) 114 (22): 631.

https://doi.org/10.1182/blood.V114.22.631.631

Published: 2009

Journal Articles

Long-Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety.

Srdan Verstovsek, MD, PhD, Hagop Kantarjian, MD, Ruben A. Mesa, MD, Jorge Cortes-Franco, MD, Animesh D. Pardanani, MBBS, PhD, Deborah A. Thomas, MD, Zeev Estrov, MD, Edward C Bradley, MD, Susan Erickson-Viitanen, PhD, Kris Vaddi, Ph.D., Richard Levy, MD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 756.

https://doi.org/10.1182/blood.V114.22.756.756

Published: 2009

Journal Articles

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

Jorge Cortes-Franco, MD, Digumarti Raghunadharao, MD, Purvish Parikh, MD, Meir Wetzler, MD, Jeffrey H. Lipton, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Hagop M. Kantarjian, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, Eric Humphriss, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 861.

https://doi.org/10.1182/blood.V114.22.861.861

Published: 2009

Journal Articles

Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia .

Jorge Cortes-Franco, MD, Hervé Dombret, MD, PhD, Philippe Schafhausen, MD, Tim H Brummendorf, MD, Nicolas Boissel, MD, PhD, Fabio Latini, MD, Laura Capolongo, Bernard Laffranchi, MD, Silvia Comis, MD

Blood (2009) 114 (22): 864.

https://doi.org/10.1182/blood.V114.22.864.864

Published: 2009

Journal Articles

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Michele Baccarani, MD, Brian J. Druker, MD, Jorge Cortes-Franco, MD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Fabrizio Pane, Susan Branford, PhD, Yu Jin, MSc, Tillmann Krahnke, PhD, Marc Rudoltz, MD, Jerald P. Radich, MD, François Guilhot, MD

Blood (2009) 114 (22): 337.

https://doi.org/10.1182/blood.V114.22.337.337

Published: 2009

NARROW

A Phase 2 study of the Combination of Omacetaxine and Imatinib in the Treatment of Patients with Chronic Myeloid Leukemia (CML) in Advanced Stages or After Failure to Imatinib.

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Outcome of Therapy-Related Acute Promyelocytic Leukemia (t-APL) with or without Arsenic Trioxide (ATO) as a Component of Frontline Therapy.

A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia (APL) Patients (PTS) Who Have Received Prior Therapy with All-Trans Retinoic Acid and Arsenic Trioxide (STAR-1 trial).

A Common but Overlooked Mechanism of BCR-ABL1 Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial.

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study.

Long-Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety.

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia .

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only